Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma

Por Zhou, Cheng-Zhi, Qin, Yin-Yin, Xie, Zhan-Hong, Zhang, Jie-Xia, Ou-Yang, Ming, Li, Shi-Yue, Chen, Rong-Chang
Publicado no Chin J Cancer Res (2014)

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment

Por Xie, Xiao-Hong, Wang, Fei, Lin, Xin-Qing, Qin, Yin-Yin, Xie, Zhan-Hong, Zhang, Jie-Xia, Ouyang, Ming, Zhou, Cheng-Zhi
Publicado no Cancer Manag Res (2020)

Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma

Por Xie, Xiao-Hong, Wang, Li-Qiang, Qin, Yin-Yin, Lin, Xin-Qing, Xie, Zhan-Hong, Liu, Ming, Zhang, Jie-Xia, Ouyang, Ming, Liu, Jun, Gu, Ying-Ying, Li, Shi-Yue, Zhou, Cheng-Zhi
Publicado no Orphanet J Rare Dis (2020)

Case report: dermatomyositis associated with lung cancer with heterogeneous morphology

Por Qin, Yin-Yin, Zhou, Cheng-Zhi, Zhu, Zheng, Guan, Wei-Jie, Lin, Xin-Qing, Liu, Chun-Li, Zhou, Yu-Ming, Wu, Hua, Gu, Ying-Ying, Zhang, De-Hua, Ou-Yang, Ming, Zhong, Nan-Shan, Li, Shi-Yue
Publicado no J Thorac Dis (2017)

The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

Por Li, Min, Zhou, Cheng-Zhi, Yang, Jin-Ji, Lu, Shun, Zheng, Di, Hu, Jie, Zeng, Hui, Lu, You, Lu, Kai-Hua, Li, Shu-Ang, Mao, Xin-Ru, Han-Zhang, Han, Lizaso, Analyn, Ye, Jun-Yi, Hu, Cheng-Ping
Publicado no Cancer Biol Ther (2019)